secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001140361-23-031794
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Q4/FY2023: VTAMA net rev $13.7M, $28.0M FY; RVT-3101 UC data positive; cash $1.7B; FY loss $1.23B
--------------------------------------------------------------------------------

- VTAMA net product revenue $13.7M in Q4, $28.0M FY; 170k prescriptions since launch; 76% US commercial lives covered.
- RVT-3101 improved efficacy from week 14 to week 56 in Phase 2b UC study; Phase 2 Crohn's initiated, data expected Q4 2024.
- VTAMA met primary and all secondary endpoints in Phase 3 ADORING 1/2 for atopic dermatitis in 813 patients including children aged 2+.
- Cash and equivalents $1.7B at March 31, 2023; cash runway into H2 2025. GAAP loss from continuing ops $175M Q4 ($0.20/share).
- FY2023 GAAP loss from continuing ops $1.23B ($1.58/share); net loss attributable to Roivant $1.01B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/brhc20054989_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-031794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer